Recruiting
Phase 1b/2 Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIde)
2025-523010-89-00· Phase 1/2· 35Pharma Inc.· Source
Recruiting
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07441200· Phase 2· NS Pharma, Inc.· Source
Recruiting
Heart Failure in Women: Epidemiological and Prognostic Insights
NCT07847983· Carolina Ortiz Cortes· Source
Not yet recruiting
Study of a DPP 4 inhibitor and an SGLT2 inhibitor used together compared with each treatment alone in adults with type 2 diabetes treated with metformin.
2025-524606-15-00· Phase 3· Tecnimede-Sociedade Tecnico-Medicinal S.A.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07481981· Phase 3· Insmed Incorporated· Source
Recruiting
Efficacy of Propranolol in Traumatic Brain Injury Patients Admitted to the ICU: A Prospective, Randomized, Triple-Blind Study
NCT07899164· Phase 3· Fundació d'investigació Sanitària de les Illes Balears· Source
Not yet recruiting
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
NCT07612657· Phase 3· VIVUS LLC· Source
Recruiting
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
NCT07318597· Phase 2· Regeneron Pharmaceuticals· Source
Recruiting
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy
2025-522979-29-00· Phase 3· Fundacion PETHEMA· Source
Recruiting
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332· Phase 3· Inhibikase Therapeutics· Source
Not yet recruiting
Treatment for Ph-negative ALL for Adults up to 65 Years
NCT07443592· PETHEMA Foundation· Source
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
Inhaled Sedation in Critically Ill Patients
NCT07000526· Phase 4· Instituto de Investigación Hospital Universitario La Paz· Source
Recruiting
A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa
NCT07284342· AbbVie· Source
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
NCT07175038· Phase 2· AllRock Bio, Inc.· Source
Recruiting
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
2024-513613-12-00· Phase 1/2· Novartis Pharma AG· Source
Recruiting
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT07039110· AbbVie· Source
Recruiting
SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial
2024-512132-29-00· Phase 2· Swiss Group for Clinical Cancer Research· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Recruiting
Evaluation of a Mobile AI-powered Decision Support System for Insulin Dosing and Glucose Prediction in Type 1 Diabetes: The glUCModel Clinical Trial Protocol
NCT07304778· Universidad Complutense de Madrid· Source
Recruiting
Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
NCT06856213· Phase 2· Grupo Español de Tratamiento de Tumores de Cabeza y Cuello· Source
Recruiting
Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
NCT06887088· Phase 2· Grupo Español Multidisciplinar de Melanoma· Source
Active, not recruiting
VITUS Post-Market Registry
NCT06832631· OrbusNeich· Source
Active, not recruiting
PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
NCT06133517· Phase 2· Fundación para el Progreso de la Oncología en Cantabria· Source
Recruiting
Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.
NCT06724159· Spanish Oncology Genito-Urinary Group· Source
Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801· Phase 3· Gossamer Bio USA, Inc.· Source
Active, not recruiting
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
2023-508235-31-00· Phase 3· Almirall S.A.· Source
Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505· Phase 1/2· Gilead Sciences· Source
Recruiting
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
NCT06320067· Phase 3· University College, London· Source
Active, not recruiting
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
NCT05983250· Phase 3· Tenax Therapeutics, Inc.· Source
Active, not recruiting
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
NCT05776004· Phase 2· Eagle Pharmaceuticals, Inc.· Source
Recruiting
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
NCT05821556· Phase 2· National Cancer Institute, Naples· Source
Recruiting
SUPRAFLEX CRUZ PMCF Study ( rEpic05 )
NCT05617599· Fundación EPIC· Source
Recruiting
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
NCT05817903· Phase 2· Consorzio Oncotech· Source
Recruiting
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
NCT06511648· Phase 2· Spanish Oncology Genito-Urinary Group· Source
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· Phase 3· Gilead Sciences· Source
Active, not recruiting
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585· Phase 3· AstraZeneca· Source
Active, not recruiting
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT
2024-517008-12-00· Phase 3· Fundacion PETHEMA· Source
Active, not recruiting
DISCUS: A Randomised Phase II Study Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
2024-518244-20-01· Phase 2· Queen Mary University Of London· Source
Active, not recruiting
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
NCT05169567· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236· Phase 3· Pfizer· Source
Active, not recruiting
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
NCT07218029· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study
NCT04431258· Phase 1/2· Ability Pharmaceuticals SL· Source
Active, not recruiting
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
NCT04432584· Phase 3· Hoffmann-La Roche· Source
Recruiting
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
NCT04043494· Phase 3· University Hospital Muenster· Source
Active, not recruiting
Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 years old, in good general health and newly diagnosed multiple myeloma.
2024-516905-22-00· Phase 3· Fundacion PETHEMA· Source
Active, not recruiting
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
NCT02066220· Phase 2/3· Universitätsklinikum Hamburg-Eppendorf· Source